title: Purulent pericarditis in rheumatoid arthritis treated with rituximab and methotrexate.
authors.affiliation: aCardiovascular Department bInternal Medicine 3, Ospedali Riuniti and University of Trieste, Trieste, Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Lutman
authors.forename: Gherardo
authors.initials: G
authors.lastname: Finocchiaro
authors.forename: Elena
authors.initials: E
authors.lastname: Abate
authors.forename: Marco
authors.initials: M
authors.lastname: Milo
authors.forename: Pia
authors.initials: P
authors.lastname: Morassi
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Sinagra
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D002305:Cardiac Tamponade / Q000139:chemically induced / Q000382:microbiology; D004562:Electrocardiography; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D010490:Pericardial Effusion / Q000139:chemically induced / Q000382:microbiology; D010493:Pericarditis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D000069283:Rituximab; D013203:Staphylococcal Infections / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab; D008727:Methotrexate